Brendan Day

Social SciencesMedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety Outcomes”.

The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety Outcomes

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2320

N/A

0.330DataRank · unranked

8 citations

Ellen Pinnow, Ilynn Bulatao, Brendan Day, Manish Kalaria, Sonja Brajovic +2 more

Postmarketing Safety‐Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002–2014: Similarities and Differences With New Molecular Entities

Clinical Pharmacology & Therapeutics(2020)10.1002/cpt.1948

N/A

0DataRank · unranked

30 citations

Ellen Pinnow, Brendan Day, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic +2 more